Project Grant K23NS142667
- This $4,164,187 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop antigen-directed therapies for autoantibody associated neuroinflammatory diseases. The project aims to facilitate the discovery of autoantibodies directed to cell surface antigens, characterize their specificity, and generate recombinant human...
- This federal Project Grant award of $414,305 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will fund research to identify key molecules and pathways underlying the process of epileptogenesis, with the goal of developing therapies to modify disease progression. The research leverages a novel algorithm called MAGIC combined with a large...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding will support a research project titled "Defining Mechanisms of Cognitive Dysfunction in Central Nervous System Autoimmunity" through July 31, 2027. The project aims to evaluate the pathogenic...
- This federal Project Grant award in the amount of $426,650 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding supports research by Trustees of Tufts College, doing business as Tufts University, to develop a hybrid strategy for efficiently deriving region-specific neural cell populations, including oligodendrocytes and neural crest progenitors,...
- This federal Project Grant award of $754,066 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to unravel the complexities of the mechanistic target of rapamycin (mTOR) signaling network in neurons. The research aims to map the entire mTOR protein interaction network in neurons, revealing how these interactions reconfigure in response to cellular...
- This Project Grant award, totaling $547,846 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to optimize and characterize small molecule GPR17 antagonists for potential treatment of multiple sclerosis (MS). The research will focus on understanding the role of the GPR17 receptor in oligodendrocyte maturation and remyelination, with the goal of...
- This federal Project Grant award of $238,356 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to study the role of the amygdala-nucleus reticularis thalami (NRT) pathway in modulating thalamocortical circuits and cortical activity, and its potential impact on seizures and neuropsychiatric comorbidities in people with epilepsy. The research, led by the...
- This $579,294 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the cell type-specific epigenetic mechanisms, particularly involving microRNAs, that regulate brain function and contribute to neurological disorders like epilepsy. The research aims to reveal the specific cell types and target mRNAs...
- This Project Grant award of $104,298 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research to delineate the activity, gating mechanism, and potential pharmacological interventions of two pathological GRIN1 variants at residue 647 (Y647C and Y647S). Patients with these variants exhibit severe cognitive developmental delay, acquired microcephaly, bilateral...
- This Project Grant award of $743,776 from the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) supports research to determine whether and when ablating mutant cells that cause epilepsy can reverse the disease in mouse models of mTOR pathway disorders. The research aims to advance the development of AAV-mediated gene therapy approaches to treat intractable epilepsy caused by mTOR pathway mutations. This work builds upon almost two decades of the recipient...
This federal Project Grant award in the amount of $219,645.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award, with a completion date of July 31, 2030, supports a research project to characterize the role of T cells, particularly T helper 17 (Th17) cells, in children with anti-NMDA receptor encephalitis (NMDARE). The key objectives are to: 1) analyze how timing of T cell treatments affects outcomes in a retrospective cohort of 362 children with NMDARE, 2) assess Th17 cells and related cytokines in blood and cerebrospinal fluid samples, and 3) use single-cell RNA sequencing to identify NMDA receptor-specific T cells and compare intracellular pathways in Th17 cells from NMDARE patients versus controls. The research is aimed at identifying a prognostic biomarker to guide optimal treatment and improve outcomes for children with this autoimmune encephalitis condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $219.6k | 8/7/25 |